Why Is Pasithea Therapeutics Stock Surging On Thursday?

Published on 24 Sep 2024 on Benzinga · via Yahoo Finance

Why Is Pasithea Therapeutics Stock Surging On Thursday?

On Thursday, Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced safety, tolerability, pharmacokinetic (PK), and preliminary efficacy data from the first 2 cohorts of patients (n=6) in its Phase 1 trial of PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition.

Read the rest of the article

NASDAQ.KTTA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Why Is Pasithea Therapeutics Stock Surging On Thursday? On Thursday, Pasithea Therapeutics Corp. ...

Benzinga · via Yahoo Finance 24 Sep 2024

Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive

Investor group comprising Camac Partners LLC, Concord Investment Partners Ltd, and Leonite Capita...

Benzinga via Yahoo Finance 14 Oct 2022

EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition

Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired AlloMek Therapeutics LLC, a privately-held...

Benzinga via Yahoo Finance 12 Oct 2022

EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With...

Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced results from a preliminary preclinical pr...

Benzinga via Yahoo Finance 11 Aug 2022

EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition

Pasithea Therapeutics Corp (NASDAQ: KTTA) has acquired Alpha-5 integrin LLC, a privately-held pre...

Benzinga via Yahoo Finance 22 Jun 2022

Pasithea Partners With Glimpse Group To Co-Develop VR Environments For Patients With Psychiatric...

Photo by Maxim Hopman on Unsplash This post contains sponsored advertising content. This content ...

Benzinga 10 Mar 2022

EXCLUSIVE: Glimpse-Pasithea To Co-Develop VR Environments For Patients With Psychiatric Disorders

Pasithea Therapeutics Corp (NASDAQ: KTTA) has partnered with Glimpse Group Inc (NASDAQ: VRAR), a ...

Benzinga via Yahoo Finance 5 Mar 2022

Pasithea To Open 3 New Clinics In The U.K. For Patients with Mental Health Issues, Each Clinic...

Image by Christina on Unsplash This post contains sponsored advertising content. This content is ...

Benzinga 25 Feb 2022

Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally

FinancialNewsMedia.com News Commentary - The prevalence of mental health disorders has risen...

WFMZ Eastern Pennsylvania and Western New Jersey 24 Feb 2022

Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028

FinancialNewsMedia.com News Commentary - Multiple Sclerosis (MS) is an immune-mediated disease of...

WFMZ Eastern Pennsylvania and Western New Jersey 3 Feb 2022